Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
|Videos|March 22, 2021
Symphonic Beauty: NMDA Glutamate Receptors
Author(s)John J. Miller, MD
Taking a closer look at the N-methyl-D-aspartate receptors...
Advertisement
John J. Miller, MD, gives a close up of NMDA glutamate receptors, and how the way they work can be a thing of beauty.
Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.
Advertisement
Related to this article
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
2
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
3
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
4
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
5